OBJECTIVE:To provide a reference for innovative drugs to enter the health insurance directory smoothly and pro-mote the rapid development of pharmaceutical industry in China. METHODS:Based on related policy study of foreign and domes-tic innovative drugs entering the health insurance directory,the policy barriers of innovative drugs entering the health insurance di-rectory were analyzed and the countermeasures were put forward. RESULTS & CONCLUSIONS:In China,the foundation of drug selection was not objective enough;the review results were so vulnerable to subjective views because of the experts selection mech-anism;the health insurance directory deletion mechanism was deficient;the waiting time for innovative drugs entering the health in-surance directory was too long;innovative drugs negotiation mechanism was imperfect,etc. It is recommended that forcibly requir-ing pharmaceutical companies should provid the related data about pharmacoeconomic evaluation;the independence and pluralism of the expert group should be enhanced;drugs in the health insurance directory should be secondarily evaluated regularly;the inno-vative drugs should be given the green channel;innovative drug price negotiation rules should be unified to promote drug informa-tion sharing.

OBJECTIVE： To design and optimize the formulation and technology of Theophylline hydrophilic gel matrix sustained-release tablets （self-made sustained-release tablets for short） based on the concept of “Quality by Design” （QbD）. METHODS： Diluent type， tablet diameter， the property of adhesive （ratio of different adhesive types）， the amount of adhesive were regarded as critical process parameters （CPPs）. Similarity factor of dissolution curves of self-made Theophylline sustained-release tablets and reference preparation and its accumulative release rate at different time points were regarded as critical quality attributes （CQAs）. L18（34） orthogonal tablet was adopted for design and trial， and secondary polynomial regression model was established. By using Modde 12.0 software， the design space and its acceptable range （PAR） were calculated through the optimal model. The optimal formulation and technology of Theophylline sustained-release tablets was determined， and validation test and Monte Carlo simulation verification were conducted. RESULTS： The optimal model with good coincidence， accuracy， validity and reproducibility was obtained， which could better fit the relationship between CQAs and CPPs. The design space and PAR value were obtained by further calculation （The optimum value of diluent was lactose； tablet diameter was 9.07-9.33 mm， and the optimal value was 9.20 mm； ratio of HPMC K4M to HPMC was 0.50-0.83， and the optimal value was 0.80； total amount of HPMC was 0.036 0-0.041 3 g per tablet， and the optimal value was 0.038 g per tablet）. The optimal formulation and technology included that ratio of theophylline， HPMC K4M and HPMC K100M were 50％， 15.48％ and 3.87％， respectively； the rest was filled with lactose and the diameter of the tablet was 9.20 mm. The results of validation confirmed that self-made Theophylline sustained-release tablets had similar in vitro release behavior compared with reference preparation. CONCLUSIONS： Based on the concept of QbD， the formulation and technology of Theophylline sustained-release tablets can meet the requirements of design， and the CPPs can be adjusted within the PAR range to meet the requirements of CQAs. This shows that the QbD concept is scientific and effective in the design and optimization of the formulation and technology of sustained and controlled release preparations.